

Wright Medical Group, Inc.
Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency
(dollars in thousands--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2011		December 31, 2011	
	International Net Sales	Total Net Sales	International Net Sales	Total Net Sales
Net sales, as reported	\$ 53,607	\$ 126,872	\$ 217,004	\$ 512,947
Currency impact as compared to prior period	(815)	(815)	(10,570)	(10,570)
Net sales, excluding the impact of foreign currency	<u>\$ 52,792</u>	<u>\$ 126,057</u>	<u>\$ 206,434</u>	<u>\$ 502,377</u>

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2011	December 31, 2010	December 31, 2011	December 31, 2010
Operating Income				
Operating income, as reported	\$ 4,105	\$ 15,169	\$ 4,593	\$ 37,174
<i>Reconciling items impacting Gross Profit:</i>				
Non-cash, stock-based compensation	349	321	1,412	1,301
Cost of sales - restructuring	571	—	2,471	—
Employment matters ⁽¹⁾	—	—	99	—
Inventory step-up amortization	32	—	32	—
Total	952	321	4,014	1,301
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	1,945	2,224	7,028	9,924
U.S. governmental inquiries/DPA related	3,379	1,283	12,920	10,902
Employment matters ⁽¹⁾	—	—	1,783	—
Product liability provision	—	—	13,199	—
Total	5,324	3,507	34,930	20,826
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	126	452	668	1,952
Employment matters ⁽¹⁾	—	—	135	—
Total	126	452	803	1,952
<i>Other Reconciling Items:</i>				
Restructuring charges	2,273	(220)	14,405	919
Operating income, as adjusted	<u>\$ 12,780</u>	<u>\$ 19,229</u>	<u>\$ 58,745</u>	<u>\$ 62,172</u>
Operating income, as adjusted, as a percentage of net sales	<u>10.1%</u>	<u>13.9%</u>	<u>11.5%</u>	<u>12.0%</u>

(1) Costs associated with settlement of certain employment matters and the hiring of a new CEO.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(in thousands, except per share data--unaudited)

	Three Months Ended		Twelve Months Ended	
	December 31, 2011	December 31, 2010	December 31, 2011	December 31, 2010
Net Income				
Income (loss) before taxes, as reported	\$ 2,406	\$ 13,736	\$ (6,655)	\$ 30,921
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	2,420	2,997	9,108	13,177
U.S. governmental inquiries/DPA related	3,379	1,283	12,920	10,902
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	—	—	4,099	—
Restructuring charges	2,844	(220)	16,876	919
Employment matters ⁽¹⁾	—	—	2,017	—
Product liability provision	—	—	13,199	—
Inventory step-up amortization	32	—	32	—
Income before taxes, as adjusted	11,081	17,796	51,596	55,919
Provision (benefit) for income taxes, as reported				
	\$ 1,243	\$ 4,867	\$ (1,512)	\$ 13,080
Non-cash, stock-based compensation	853	1,144	2,946	4,410
U.S. governmental inquiries/DPA related	1,754	81	5,125	2,266
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	—	—	1,599	—
Restructuring charges	1,591	(67)	6,165	376
Employment matters ⁽¹⁾	—	—	720	—
Product liability provision	—	—	4,740	—
Inventory step-up amortization	12	—	12	—
IRS audit liability	(1,041)	—	(1,041)	—
Provision for income taxes, as adjusted	\$ 4,412	\$ 6,025	\$ 18,754	\$ 20,132
Effective tax rate, as adjusted	39.8%	33.9%	36.3%	36.0%
Net income, as adjusted	\$ 6,669	\$ 11,771	\$ 32,842	\$ 35,787

(1) Costs associated with settlement of certain employment matters and the hiring of a new CEO.

Wright Medical Group, Inc.
Reconciliation of As Reported Results to Non-GAAP Financial Measures
(continued)

	Three Months Ended		Three Months Ended	
	December 31, 2011		December 31, 2010	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net income	\$ 1,163	\$ 6,669	\$ 8,869	\$ 11,771
Interest expense on convertible notes	N/A	137	935	935
Diluted net income	\$ 1,163	\$ 6,806	\$ 9,804	\$ 12,706
Basic shares	38,430	38,430	37,962	37,962
Dilutive effect of stock options and restricted shares	243	243	147	147
Dilutive effect of convertible notes	N/A	891	6,126	6,126
Diluted shares	38,673	39,564	44,235	44,235
Net income per share, diluted	\$ 0.03	\$ 0.17	\$ 0.22	\$ 0.29

	Twelve Months Ended		Twelve Months Ended	
	December 31, 2011		December 31, 2010	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
Basic net (loss) income	\$ (5,143)	\$ 32,842	\$ 17,841	\$ 35,787
Interest expense on convertible notes	N/A	1,203	N/A	3,740
Diluted net income	\$ (5,143)	\$ 34,045	\$ 17,841	\$ 39,527
Basic shares	38,279	38,279	37,802	37,802
Dilutive effect of stock options and restricted shares	N/A	136	159	159
Dilutive effect of convertible notes	N/A	1,909	N/A	6,126
Diluted shares	38,279	40,324	37,961	44,087
Net income per share, diluted	\$ (0.13)	\$ 0.84	\$ 0.47	\$ 0.90

	Three Months Ended		Twelve Months Ended	
	December 31, 2011	December 31, 2010	December 31, 2011	December 31, 2010
	Net Income per Diluted Share			
Net income (loss), as reported, per diluted share	\$ 0.03	\$ 0.22	\$ (0.13)	\$ 0.47
Interest expense on convertible notes	0.00	N/A	0.03	0.08
Effect of convertible notes on diluted shares	(0.00)	N/A	0.01	(0.07)
Non-cash, stock-based compensation	0.04	0.04	0.15	0.20
U.S. governmental inquiries/DPA related	0.04	0.03	0.19	0.20
Deferred financing fees and transaction costs associated with Convertible Notes Tender Offer	—	—	0.06	—
Restructuring charges	0.03	(0.00)	0.27	0.01
Employment matters ⁽¹⁾	—	—	0.03	—
Product liability provision	—	—	0.21	—
IRS audit liability	0.03	—	0.03	—
Net income, as adjusted, per diluted share	\$ 0.17	\$ 0.29	\$ 0.84	\$ 0.90

(1) Costs associated with settlement of certain employment matters and the hiring of a new CEO.